Eli Lilly & Co

Eli Lilly & Co. demonstrates a structured governance process for ensuring its lobbying activities align with its environmental and broader climate strategy, with oversight beginning at the board level. "Our board exercises governance oversight of our political expenditures and lobbying activities, ensuring our commitment to stewardship of corporate funds and risk minimization with respect to such activities," and the Directors and Corporate Governance Committee receives "semi-annual updates on political engagement, including information on ... trade association memberships." To maintain consistency between policy efforts and business strategies, the company has established a "formal Legislative and Regulatory Tracking Committee (LRTC) that includes representatives from our global health, safety, and environment (HSE) team; Legal; and Corporate Affairs." This committee "meets at least semi-annually" to oversee U.S. federal legislative and regulatory topics and "coordinates Lilly's activities among various trade groups involved in environmental advocacy." Globally, the EU HSE Regulatory Tracking Group and non-U.S. HSE representatives work closely with the "Director of Corporate Health, Safety and Environment" to monitor and align emerging environmental rules and regulations. The company further affirms it will "actively participate with government agencies and other appropriate organizations in the development of environmental laws and regulations" and publicly commits to align its engagement with the "goals of the Paris Agreement." We found no evidence of a publicly available, in-depth climate-lobbying audit or third-party review assessing the alignment of its lobbying activities.